Jonathan Seideman
Overview
Explore the profile of Jonathan Seideman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
159
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stowell N, Seideman J, Raymond H, Smalley K, Lamb R, Egenolf D, et al.
Respir Res
. 2009 Jun;
10:43.
PMID: 19486528
Background: The immune mechanisms associated with infection-induced disease exacerbations in asthma and COPD are not fully understood. Toll-like receptor (TLR) 3 has an important role in recognition of double-stranded viral...
2.
Chang M, Seideman J, Sofou S
Bioconjug Chem
. 2008 May;
19(6):1274-82.
PMID: 18505278
Targeted alpha-particle emitters are promising therapeutics for micrometastatic disease. Actinium-225 has a 10-day half-life and generates a total of four alpha-particles per parent decay rendering (225)Ac an attractive candidate for...
3.
Liu X, Das A, Seideman J, Griswold D, Afuh C, Kobayashi T, et al.
Am J Respir Cell Mol Biol
. 2007 Mar;
37(1):121-8.
PMID: 17379849
Apoptosis of lung structural cells is crucial in the process of normal tissue repair. Insufficient apoptosis of lung fibroblasts may contribute to the development of fibrosis. Since the CC chemokine...
4.
Kruszynski M, Stowell N, Das A, Seideman J, Tsui P, Brigham-Burke M, et al.
J Pept Sci
. 2005 Jun;
12(1):25-32.
PMID: 15942931
Novel analogs of human monocyte chemoattractant protein 1 (MCP-1) were designed, synthesized and characterized to be used as tools to generate monoclonal antibodies as potential human therapeutics. MCP-1 and three...
5.
Seideman J, Peritt D
J Immunol Methods
. 2002 Aug;
267(2):165-71.
PMID: 12165438
We describe the development of a robust and sensitive assay system (detection limit <500 pg/ml biotin-IL-6, K(d)=75 ng/ml), using Luminex-100 microspheres, that could effectively screen for neutralizing antibody whenever a...